Eutropics Pharmaceuticals Approved to Perform Patient Samples Testing

September 20, 2013

Eutropics can now  begin clinical laboratory operations for the PraediCare Dx™ portfolio of diagnostics tests

Cambridge, MA, September 20, 2013 - Eutropics Pharmaceuticals Inc. announced today that Eutropics successfully concluded its Massachusetts state inspection yesterday and has been approved to perform patient samples testing under the Massachusetts Department of Public Health Clinical Laboratory Program.

This approval to operate as a Massachusetts licensed CLIA registered  lab marks a significant milestone for Eutropics, allowing the company to begin clinical laboratory operations for the PraediCare Dx™ portfolio of diagnostics tests at our Cambridge, MA labs.

Eutropics is positioned to provide this important technology for guiding drug development and use.


About PraediCare Dx

Eutropics’ PraediCare Dx platform technology delivers medically useful in vitro diagnostic assays. The tests may improve patient outcome by directing the best treatment options and also may provide a biomarker for guided cancer drug development. Based on clinical evidence, the PraediCare Dx technology platform delivers unique understanding into a cancer cell’s ability to respond to chemotherapies that induce programmed cell death (apoptosis), enabling the physician to choose the treatment option most likely to benefit the individual patient.

Tests based on the PraediCare Dx technology are being investigated for use in treating acute myelogenous leukemia (AML) and multiple myeloma (MM). A recently completed validation study in uniformly treated AML patients indicate that the test provides actionable data to physicians. PraediCare Dx is currently being verified in repeat studies with academic and pharmaceutical partners. These validation studies for predicting response to standard-of-care are anticipated to be completed in fourth quarter of 2013. Tests for CLL, ALL and DLBCL have been developed for future clinical studies.

About Eutropics Pharmaceuticals

Eutropics is addressing the need for improving the treatment of aggressive forms of leukemia, myeloma, lymphoma, and other cancers. The company is developing a novel diagnostic technology that will guide the use of established and experimental therapeutics, enabling the delivery of personalized medicines to patients suffering from cancer. <a href="; data-rapid_p="1">


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.